Relmada acquires neurosteroid from Asarina
Relmada in-licenses Tourette syndrome drug from Asarina
US CNS specialist Relmada Therapeutics has announced the acquisition of sepranolone, a Phase IIb ready neurosteroid, from Sweden’s Asarina Pharma, being developed for the potential treatment of Tourette syndrome (TS) and other compulsive disorders.
Relmada, which has turned to strategic options after scrapping two phase 3 trials in major depressive disorder (MDD), is ...
Mizuho (NYSE:MFG) analysts maintained their Neutral rating on Relmada Therapeutics Inc (NASDAQ:RLMD), with a steady price target of $1.00, following the announcement of a new acquisition. The stock, ...
Relmada purchases Sepranolone, a Phase 2b ready asset, for the treatment of Tourette syndrome (TS) and other compulsion-related conditions from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback